Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
In 2013 a phase III trial In Japan (JGOG 3016) showed a survival advantage when the normal chemotherapy after initial surgery for ovarian cancer was altered. Usually chemo is given as at 3-weekly intervals with 6 doses as a minimum, more if serum markers show the need. Instead of this the frequency was changed to weekly.
Because of reported increase in toxicity and in order to replicate the findings a prospective randomly allocated phase III trial (ICON8) began in 2011. 1566 women with ovarian cancer were allocated into two groups; either 3-weekly or weekly chemotherapy commenced, with both groups having the same chemotherapeutic agents.
Parameters measured in the trial were quality of life, survival and neuropathy. Results showed no improvement in survival with more frequent dose regimes. Quality of life measurements at 9 months were similar for both groups, though the weekly dose group reported adverse effects during chemo more often. Both groups had neuropathy, with a later onset for those having extended chemo suggesting it may be related to total dose received.
No comments:
Post a Comment